From the *Division of Pediatric Gastroenterology and Nutrition, MassGeneral Hospital for Children, Harvard Medical School, Boston, MA
the †Department of Pediatrics, Harvard Medical School, Harvard University, Boston, MA
the ‡Center for Celiac Research and Treatment, MassGeneral Hospital for Children, Harvard Medical School, Boston, MA
the §Mucosal Immunology and Biology Research Center, MassGeneral Hospital for Children, Boston, MA
the ‖Celiac Research Program, Harvard Medical School, Boston, MA.
Received June 6, 2022; accepted July 25, 2022.
Sources of Funding: Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number K23DK122127 to M.M.L. and DK104344 (to A.F.)
M.M.L has received research support from Glutenostics LLC. V.K. has served on an advisory board for Takeda Pharmaceuticals. A.F. is co-founder and stock holder of Alba Therapeutics, is consultant with 9 Meters Biopharma, Milky Way Life Sciences, Precidiag, and Viome. M.M.L. has served on an advisory board for 9 Meters Biopharma and acts as a consultant for Anokion. She has served as site-PI for Takeda Pharmaceuticals and 9 Meters Biopharma. A.A.I. reports no conflicts of interest.
Address correspondence and reprint requests to Maureen M. Leonard, MD, MassGeneral Hospital for Children, 55 Fruit St, Boston, MA 02114 (e-mail: [email protected]).
